To the Editor: Obadia et al. (Dec. 13 issue)(1) describe the results of the MITRA-FR trial (Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation), a randomized, controlled trial of this device for percutaneous mitral-valve repair in patients with chronic heart failure and severe secondary mitral-valve regurgitation. The trial showed no clinical benefit for percutaneous correction of functional mitral regurgitation over medical therapy alone. The cardiovascular death rate at 1 year (21.7% in the intervention group and 20.4% in the control group) was unusually high and much higher than the rates reported in the largest real-world MitraClip registries . . .
Percutaneous Repair for Secondary Mitral Regurgitation
Margonato, Alberto
2019-01-01
Abstract
To the Editor: Obadia et al. (Dec. 13 issue)(1) describe the results of the MITRA-FR trial (Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation), a randomized, controlled trial of this device for percutaneous mitral-valve repair in patients with chronic heart failure and severe secondary mitral-valve regurgitation. The trial showed no clinical benefit for percutaneous correction of functional mitral regurgitation over medical therapy alone. The cardiovascular death rate at 1 year (21.7% in the intervention group and 20.4% in the control group) was unusually high and much higher than the rates reported in the largest real-world MitraClip registries . . .I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
